PATRYS Ltd (PAB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -2.365x

Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PATRYS Ltd market cap and net worth for the company's overall valuation and market capitalisation.

PATRYS Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

PATRYS Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency. Explore PATRYS Ltd cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Mason Graphite Inc.
V:LLG
-0.007x
W.A.G payment solutions plc
LSE:EWG
0.376x
Creative Media & Community Trust Corporation
NASDAQ:CMCT
0.014x
SynBiotic SE
F:SBX
N/A
Telecom Plus PLC
LSE:TEP
0.263x
Rochester Resources Ltd
V:RCT
-0.031x
Sanwil Holding SA
WAR:SNW
0.000x
Together Startup Network Ltd
TA:TGTR
-0.149x

Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. View PATRYS Ltd (PAB) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$732.87K
≈ $518.56K
AU$-1.77 Million
≈ $-1.26 Million
-2.421x -362.62%
2024-06-30 AU$3.47 Million
≈ $2.46 Million
AU$-1.82 Million
≈ $-1.28 Million
-0.523x +38.08%
2023-06-30 AU$6.84 Million
≈ $4.84 Million
AU$-5.78 Million
≈ $-4.09 Million
-0.845x -30.75%
2022-06-30 AU$13.43 Million
≈ $9.50 Million
AU$-8.68 Million
≈ $-6.14 Million
-0.646x -100.76%
2021-06-30 AU$12.04 Million
≈ $8.52 Million
AU$-3.88 Million
≈ $-2.74 Million
-0.322x +37.06%
2020-06-30 AU$4.88 Million
≈ $3.45 Million
AU$-2.50 Million
≈ $-1.77 Million
-0.512x -2789.46%
2019-06-30 AU$7.30 Million
≈ $5.16 Million
AU$-129.19K
≈ $-91.41K
-0.018x +93.81%
2018-06-30 AU$7.29 Million
≈ $5.16 Million
AU$-2.09 Million
≈ $-1.48 Million
-0.286x +40.32%
2017-06-30 AU$2.66 Million
≈ $1.88 Million
AU$-1.28 Million
≈ $-903.55K
-0.480x -13.93%
2016-06-30 AU$3.64 Million
≈ $2.57 Million
AU$-1.53 Million
≈ $-1.08 Million
-0.421x +59.39%
2015-06-30 AU$3.97 Million
≈ $2.81 Million
AU$-4.11 Million
≈ $-2.91 Million
-1.036x -153.21%
2014-06-30 AU$12.43 Million
≈ $8.80 Million
AU$-5.09 Million
≈ $-3.60 Million
-0.409x -67.78%
2013-06-30 AU$10.77 Million
≈ $7.62 Million
AU$-2.63 Million
≈ $-1.86 Million
-0.244x +19.13%
2012-06-30 AU$12.45 Million
≈ $8.81 Million
AU$-3.75 Million
≈ $-2.66 Million
-0.302x +20.56%
2011-06-30 AU$13.47 Million
≈ $9.53 Million
AU$-5.11 Million
≈ $-3.62 Million
-0.380x +18.00%
2010-06-30 AU$15.23 Million
≈ $10.78 Million
AU$-7.05 Million
≈ $-4.99 Million
-0.463x -13.05%
2009-06-30 AU$17.72 Million
≈ $12.54 Million
AU$-7.26 Million
≈ $-5.14 Million
-0.410x -26.26%
2008-06-30 AU$22.98 Million
≈ $16.26 Million
AU$-7.45 Million
≈ $-5.27 Million
-0.324x --

About PATRYS Ltd

AU:PAB Australia
Market Cap
$7.96 Million
AU$11.24 Million AUD
Market Cap Rank
#27708 Global
#1369 in Australia
Share Price
AU$0.03
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.05
All Time High
AU$0.07
About

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more